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INTRODUCTION

Viruses have been implicated as oncogenic agents as early as
1903 by Borel

(1).

Utilizing recently developed chemical

purification techniques, numerous tumor filtrates have yielded
virus consistently associated with oncogenicity

(1).

However,

other animal cancers morphologically sindliar to those produced by
viruses have failed to yield virus.
viruses have demonstrated
be induced.

Experiments with the oncorna

(2) that in the proper host tumors could

Little o r no virus was recovered from these transformed

cells and no cytopathic effect on the cell was observed.

This

transformed state remained in daughter cells with no virus
production.

However, the question of whether or not certain

viruses are the etiologic agents of certain

(or all)

cancers

remains unanswered.
Unlike other infectious agents, viruses contain either ribo
nucleic

(RNA) or deoxyribonucleic acid

materials.

(DNA) as their genomic

Tumorogenic viruses have been isolated from both the

RNA- and DNA-containing groups.
(oncornaviruses)
mice, and cats

The RNA-containing viruses

have been implicated in leukemias in chickens,

(1) and a mammary carcinoma in mice

(2).

The DNA-

containing viruses have been established as the causative agent for
Marek's disease

(3) in turkeys and strong evidence has been

advanced that these viruses are etiologic agents for certain types
of cervical carcinomas in humans

(4).

1
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To date the viral etiology o f any human cancer has not been
proven conclusively.

However, many recent studies

(5,6,7,8,9)

in

vitro and in vivo on known animal tumor viruses indicate several
possible mechanisms by which occult viruses or genetic viral
information could reside within a cell for hundreds of cell
generations before being expressed.
Other studies

(10) aimed at developing antiviral chemo

therapeutic agents showed that many drugs capable of blocking viral
specific DNA metabolism also interfered with the tumorogenic
activities of DNA-containing viruses.

An adventitious finding was

that some of these same drugs inhibited transformation by onco
rnaviruses

(11,12).

Since the oncornaviruses contained only RNA as

their genomic material,

these experiments suggested a DNA dependent

step in transformation, a potential reverse transcription from the
genomic RNA to a DNA intermediate.
of nucleic acid metabolism

At this time,

1964, the concepts

(Figure 1) proposed by Watson and Crick

(13) did not include transcription from RNA to a DNA product
(reverse transcription).
In an effort to explain the above
results Temin

(or certain of the above)

(14) proposed the provirus theory.

This theory was

based upon the well known phenomenon of bacteriophage lysogenicity
together with observations on the effect of metabolic inhibitors on
oncornavirus replication.

Essentially, the theory proposed required

the horizontal transmission of the intact viral RNA by transcription
of the viral genome to a DNA copy.

This would represent a reversal

of the accepted scheme of transcription of DNA to RNA.

The
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resultant DNA copy would then be integrated into the c e l l 1s genome
and remain latent until some future stimulating or derepressing
event.

It was not until a decade later that Temin

Baltimore

(15)

and

(16) established independently and conclusively the

presence of an enzyme which could catalyze the reverse transcription.
The enzyme, termed reverse transcriptase
two different oncornaviruses.

(RT), was isolated from

Following these original observations

all oncornaviruses examined have yielded RT and all non-tumorogenic
RNA viruses tested, with the possible exceptions of Visna and foamy
viruses, have lacked this enzyme activity

(17).

Recently Temin has revised his provirus theory
the protovirus theory)

(now known as

now stating that it is unnecessary to

transmit an intact genome for tumor induction

(18,19).

Supportive

experimental evidence for this model was the demonstration
of an endonuclease and a ligase in the virion.

(20,21)

These enzymes were

presumed to aid in the insertion of the viral DNA copy by uncoup
ling the cell's genome and coupling the viral DNA copy to this
genomic material.

Two general types of oncornaviruses were

proposed by Temin - complete and incomplete viruses.

Complete

viruses were capable of the normal horizontal transmission of
genetic information and ultimately complete oncogenic expression
with virion production.

Incomplete viruses integrated a partial

DNA copy of viral genome and acted in conjunction with a normal
cellular component for oncogenic expression.
Temin

In recent studies

(22,23) has established that reverse transcription is a

normal process during differentiation.

He postulated that when the
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incomplete viral gene is located near or adjacent to a host gene,
which undergoes transcription during differentiation,

then the

viral gene may be altered to an oncogene expressing its oncogenic
potential.
Alternate proposals have been made to explain the viral
transformation of normal cells to the tumorogenic state and the
inability to isolate virus from the induced tumor.

Huebner

(24,25)

advanced the oncogene theory which states that all cells of the
body possess foreign genetic information inserted during evolution
ary development.

Malignancy is expressed by derepression of the

replication of this genetic material.

The primary difference

b etween Huebner's and Temin's hypotheses is that the former
p roposed the o n c o g e n e ’s presence in all cells
transfer)

(because of in ovo

while the latter asserted that the oncogenic information

was present only in transformed cells.

Credence has been given

to the oncogene theory through studies in many laboratories
in which diverse somatic cells,

(5,7)

not known or demonstrated to have

virus infections, wer e induced to produce viruses on exposure to
the nucleosides 5-bro- or 5-iododeoxyuridine

(IUDR or B U D R ) .

These viruses were invariably C-type particles which have been
frequ%ntly associated with oncornaviruses.
Since the original discovery of a RT several hundreds of
publications have confirmed and extended these observations.
T here remains little doubt that all oncornaviruses of animals
have a RT

(2), that the levels of RT activity can be used to

indicate the concentration of virus

(19), and that RT activity in
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animal tissues is often associated with the presence of onco
rnaviruses

(19).

Based upon these facts, several laboratories

assayed the levels of RT activity in those human tumor tissues
which closely resembled their virus-containing animal counterparts.
These studies showed that the enzyme was associated with 70S RNA
from patients with leukemias
30), and breast cancer

(26,27),

(31,32).

sarcomas

(28), lymphomas

(29,

The significance of these findings

is that the 70S RNA is unique to RNA tumor viruses

(2) and that the

enzyme activity is frequently associated with the electron
microscopic observations of C-type viral particles found in these
tissues

(19).

The purpose of the study to be presented was to develop an
assay clinically applicable to detect tumorous tissue and to apply
the test as a screen for the presence of unrecognized developing
tumors.

The RT assays previously employed had been primarily

developed as experimental laboratory procedures and were not
applicable for routine clinical screening.
obvious immediately.

Several obstacles were

First, all human tumors were probably not of

viral origin and certainly not exclusively induced by oncorna
viruses.
sample.

Second, the enzyme must be detectable in a small clinical
Third, the enzyme must be detectable in a biologically

heterogeneous sample since exhaustive purification of 70S RNA seemed
beyond most laboratory capabilities.
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MATERIALS

The artifical oligonucLeotide,
adenosine nucleic acid

oligodeoxythmidine*polyribo-

(olig'cc c3T*poly rA) was obtained from

Collaborative Research, Inc.

Thymidine methyl-H-^ 5'-triphosphate,

tetrasodium salt was o b t a i n e d f r o m New England Nuclear.

The

deoxyribonucleotide triphosphates were purchased from Sigma Chemical
Company.

Highly polymerized. calf thymus DNA,

Sigma Chemical Company.

type V, was from

PutfifSLed murine Rauscher leukemia virus

(RLV) was received from ElectSro-Nucleonics Laboratories,
Nonidet

(NP-40) was a gift f m m

the Shell Oil Company.

Inc.
All routine

chemicals used were p u r c h a s e d firom Sigma Chemical Company.
was purchased from The Upjolia Company.

Ready-Solv scintillation

fluid was from Beckman Chemicals and Scintisol Complete was
purchased from Isolab,

Heparin

Inc.
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METHODS

Assay Procedures for Reverse Transcriptase

Since the purpose of this study was to develop a clinically
adaptable assay for RT, the known methods for RT assay were first
tested and modified as necessary.

For simplification the various

procedures are presented in chronological order, with modifications
given in the text.

Method I

The method of Kiessling
following reasons:

(33) was examined first for the

1) it appeared capable of detecting enzyme in

small amounts of human plasma,

2) it did not require complicated

concentration and purification procedures, and 3) it was not
necessary to perform extensive purification procedures to obtain
the enzyme and template.

The unmodified reaction is detailed in

the following description.
The reagents

(Table 1) were dissolved in a total volume of

100 ml of water at pH 8.3.

To this was added 10 yl of purified

avian myeloblastosis virus enzyme.

The mixture was incubated for a

predetermined time and stopped by the addition of 100% trichloro
acetic acid

(w/v)

(TCA).

The precipitated material was collected

immediately on a 0.2 millimicron
filter

(my) Millipore nitrocellulose

(prior to use the filter was washed with 5 ml of washing

mixture [w m ] consisting of 8% TCA in 0.02M N a ^ P O ^ and 0.04M
7
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Na4P 2C>7 *5H20) .

The filter and TCA precipitate were first washed

with 10 ml followed by 5 ml of WM, removed and placed in a
scintillation vial.

To this vial was added 0.5 ml of 0.5N

perchloric acid and the vial was incubated at 70°C for 40 minutes.
After incubation 10 ml of Ready-Solv scintillation fluid was added
and the sample assayed for radioactivity in a Packard Tri-Carb
liquid scintillation spectrometer with a counting efficiency of
approximately 30%.

Method II

This was the procedure used by Schlom and Spiegelman
the detection of RT in human milk.

(31)

for

Crude enzyme samples were

suspended in 50 pi of 0.01M tris(hydroxymethyl)aminomethane
hydrochloride

(Tris)(pH 8.3)

dithiothreitol

containing 0.03% IIP-40 and 0.1M

(DTT) and incubated at 4°C for 10 minutes.

To begin

each reaction 10 pi of sample containing RT and the endogenous RNA
template of the virion was added to a 100 pi volume of reaction
mixture

(Table 2).

specified time.
of carrier DNA

This was then incubated at 37°C for the

The reaction was stopped by the addition of 10 pi
(1 mg/ml)

and 0.3 ml of 100% TCA

(w/v), modified

from 10% TCA, and allowed to stand for 20 minutes.

The terminated

reaction mixture was filtered through a 0.3 mP Millipore filter,
modified from a ground glass filter, pretreated by immersion in WM
followed by rinsing with 5 ml of WM.

The reaction vessel was

washed with an additional 5 ml of W M and finally treated as
described previously in method I.
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Method III

This procedure is that of Roy-Burman

(34) designed for the

detection of RT using the artificial template oligo dT*poly rA.
The procedure,

in our hands, yielded consistently reproducable data

and, with only minor changes, was used throughout the remainder of
the study.

The sample was suspended in 50 yl of 0.0114 Tris

(pH 8.3)

containing 0.03% NP-40 and 0.114 DTT and incubated at 4°C for 10
minutes.

A 10 yl fraction of this preincubated sample was added

to 100 yl of reaction mixture
indicated times.
of WM

(Table 3) and incubated at 37°C for the

The reaction was stopped by the addition of 0.8 ml

(10% TCA [w/v] and 1% Na^P20-y•5 H 2 O) and 0.1 ml of carrier DNA

(1 m g / m l ) .

Roy-Burman h ad originally used a different buffer for

the TCA, but this buff e r proved to be better.

It was then allowed

to stand for 10 minutes and filtered through a 0.3 my Millipore
nitrocellulose filter
WM.

(prewashed with 3 ml of WM)

using 18 ml of

The filter was then placed in the scintillation vial and 0.5

ml of 0.5N perchloric acid added.
at 70°C for 30 minutes.

The vial was capped and incubated

Ten ml of Scintisol Complete was added and

the sample assayed for radioactivity in a Packard Tri-Carb
scintillation spectrometer.

Heparin Inhibition Study

Blood was collected in vacutainers containing heparin
USP/ml)

or ethylenediaminetetraacetate

(28.6

(EDTA)(1.44 m g / m l ) , glass

beads or with citrate-phosphate-dextrose solution

(CPD).

The

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

plasma collected with CPD was stored at -70°C prior to use; all
other samples were collected on the day of the experiment.

Plasma

was separated from cells by centrifugation at 23°C for 10 minutes
at 220 x g and clarified by centrifugation at 4°C for 10 minutes at
7800 x g.

The particulate fraction was centrifuged at 4°C for 30

minutes at 215,000 x g, the supernatant fluid decanted and the
pellet resuspended in 110 yl of virus buffer

(0.1M NaCI, 0.01M Tris

[pH 7.0], and 0.001M E D T A ) .
To detect RLV in the presence of the various anticoagulants,
the virus was added subsequent to the clarification step.

Studies

on the effect of dilution of the plasma particulate fraction were
carried out by first resuspending this fraction in ICO yl of virus
buffer.

Dilutions of 1:10 and 1:1000 were made with virus buffer.

Fifty yl of RLV was added to a 50 yl portion of each dilution.
RLV was added to either virus buffer or virus buffer with
heparin

(57.2 USP/ml)

study.

A 10 yl fraction of either buffer A

0.002 yl HP-40,

to make a 1:1

(v/v) dilution for the kinetic

0.05 ymoles M g C l 2 *6H20,

or buffer A with heparin

(0.05 ymoles DTT,

5.0 ymoles Tris [pll 7.9])

(28.6 USP/ml) was added to the reaction

mixture during incubation where indicated.

Assay method III was

used for the quantitation of RT in all samples prepared.

Clinical Sample Preparation

Two problems were encountered in preparing clinical samples
for assay.

First, the anticoagulants used for the collection of

pla s m a samples interfered with the assay by differing amounts.
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Secondly, when the particulate fraction was pelleted by
centrifugation, resuspension of the pellet was difficult.

Two

methods were evaluated for preparation of these samples before
arriving at a satisfactory procedure.

Method I

Venous blood was collected in vacutainers containing EDTA
(1.44 mg/ml).

Plasma was collected by centrifugation at 1000 x g

for 10 minutes at 23°C and clarified by centrifugation at 7800 x g
for 10 minutes at 4°C.

The clarified plasma was centrifuged at

215,000 x g for 30 minutes at 4°C and the pellet was resuspended
in 110 hi of virus buffer with the aid of a rotating glass probe.
A 100 pi portion of this suspension was removed and preincubated in
0.25% NP-40 for 10 minutes at 4°C.

The RT activity was measured

according to enzyme m e thod III.

Method II

A plasma sample was centrifuged at 31,000 x g for 10 minutes
at 4°C and the resultant pellet was resuspended in 100 Ml of
incubation mixture

(1.5% NP-40 and 0.048M DTT) plus 100 Ml of virus

buffer followed by incubation for 10 minutes at 23°C.

The RT

activity was determined with the enzyme method III.

Method III

A plasma sample was placed in a nitrocellulose centrifuge tube
containing a fitted flat-topped teflon boss with a circular 12 mm

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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coverslip on top of the boss.

This centrifuge tube with plasma

was then centrifuged at 31,000 x g (maximum radius)
at 4°C in a SW65 rotor.

for 10 minutes

The pellet on the coverslip was resuspended

with 250 yl of virus buffer and 100 yl of incubation mixture and
incubated for 10 minutes at 23°C.

The RT activity was determined

using the enzyme assay method III.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

RESULTS AND DISCUSSION

Kiessling's studies

(33) indicated a quantitative difference

in plasma polymerase activity between normal and chronic lymphocytic
leukemia

(CLL) patients.

It should be emphasized however that his

system, according to recent data

(19,36) would not differentiate

RT from other DNA polymerase activity present.

The assay system was

unique in that human plasma was used directly without gradient
purification or collection of large quantities of leucocytes.

The

relative simplicity of the procedure indicated that it was a logical
choice to monitor RT activity in cancer patients.

The decision to

determine the RT activity in human plasma was further supported by
Gallo

(17).

Gallo reported an increased polymerase activity in

acute lymphocytic leukemia

(ALL), acute myelocytic leukemia

and chronic myelocytic leukemia

(AML),

(CML) when using plasma samples.

The data in Figure 2 illustrate incorporation of thymidine mono
phosphate

(TMP) over a 40 minute incubation at 37°C when

Kiessling's procedure was repeated.

This demonstrated that this

procedure could be repeated in the laboratory using partially
purified RT.

The labelled thymidine triphosphate

(H-^-TTP) used in

these early experiments had a low specific activity
compared to that used in later procedures.

(5 Ci/mM) when

Actually in the reaction

mixture the specific activity was much lower (2 pCi/mM) because
unlabeled TTP was also added to the reaction.

This addition was

made because the low concentration of TTP in the reaction with only
13
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H 3 —TTP was rate limiting for the polymerase assay.
minutes a total of 800 counts per minute

During 30

(cpm) of TMP was incorpor

ated using method I.
Although easily performed and yielding satisfactory results,
two important factors negated further use of this procedure.

First,

the template was nicked DNA which is not thought specific for RT
(25,42,43).

Second, the quantitative differences

(33) between

normal and CLL patients was only 500 cpm after a 90 minute incuba
tion.
Shortly after the appearance of Kiessling's report Schlom and
Spiegelman

(31), studying RT activity in human colostrum, presented

an RT assay for the endogenic0 RNA template of oncornaviruses.
Figure 3 is a kinetic curve of a RT assay using method II and shows
a linear incorporation, demonstrating that enzyme activity can be
detected by using the RNA from the virion as the only template in
the reaction.

During 30 minutes only 400 cpm of TMP was incorpor

ated using method II.

Although only 400 cpm was detected, this

incorporation was more representative of RT activity than was the
incorporation observed using the nicked DNA template in method I
since the endogenous RNA was utilized.

This procedure gave valid

experimental results, yet it was not readily adaptable to routine
clinical screening because of the time required for isolation and
purification of virus.

It was obvious that a simpler, rapid and

more specific assay was required.
In 1972, investigating DNA polymerase, Roy-Burman

(34)

reported experiments which showed an increase in TMP incorporation

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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which did not require complicated purification procedures.
Furthermore, high specific activity
became commercially available;

(40 Ci/mM)

for the TTP now

the high specific activity would

measurably increase assay sensitivity since more II -TTP would be
available for incorporation into the DNA product.

To increase the

product formation the artificial template oligo d T ’poly rA was
added to the reaction mixture.

This is a specific template for

RT as evidenced by the work of Temin and Baltimore
(36).

Results by Verma

(19) and Wells

(35) demonstrated two separate enzyme

activities within the virion, a RNA template dependent and a DNA
template dependent activity, both forming a DNA product.

The RNA-

dependent activity was established and completed within the initial
10 minutes of incubation while the DNA-dependent activity was not
established until a sufficient concentration of DNA was present
in the reaction mixture.

The best sample of a DNA product formed

only because of RT activity should then be taken during the initial
10 minutes of incubation.

Because the amount of DNA formed during

this initial period was small, it was suggested by Verma that the
second enzyme activity be utilized to amplify this initial RT
product.

It was further recommended that an incubation period of

30 minutes or less be used for amplification.
The results in Table 4 show a rate of TMP incorporation of
0.046 picomoles per minute with a backround of less than 0.01
picomoles.

To demonstrate that this incorporation was virus

dependent, the original concentration of virus particles was
diluted and qualitatively correlated to TMP incorporation

(Table 4).
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Comparing the actual value to the expected value for 6.6 x 10^
virions per ml, it was seen that assay method III was only able to
detect a difference of one-half a power of ten of virions per ml.
The undiluted sample was used as a reference point to compute the
expected virus concentration when the TMP incorporation was 0.06

0
picomoles.
expected.

It was determined that 3 x 10

virions per ml was

Also, the data presented in Table 4 show that the lowest

level of detection by the RT assay method was at a concentration of
6 x 10^ RLV virions per ml of virus buffer.
To further demonstrate that the assay was dependent upon a
RNA template, RNase was incorporated into the reaction.
strating that only 0.01 picomoles of TMP

By demon

(Table 5) was incorporated

when RNase was included into the reaction mixture,

it was concluded

that less than 5% of the DNA product formed was not dependent on
RNA sensitive to RNase.
It has been reported

(37) that various divalent cations have

an effect on the sensitivity of the assay for RT activity, e.g.,
the presence of manganese cation increased TMP incorporation three
fold over that observed with the magnesium cation.

However, the

authors did not offer an explanation for the difference.
specificity

The

(for a RNA template opposed to a DNA template) of the

reaction was lowered when the manganese cation was used.
Using the procedure as described by Roy-Burman
detection of RT activity it was established that:

(34)

for the

1) there was an

increase in H^-TMP incorporated into the DNA product over a 30
minute incubation period,

2) the product formed was dependent on

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the amount of virus present, and 3) the reaction was RNase sensitive.
With this evidence and support that the template in the reaction
mixture was specific for RT activity

(19,36), this procedure was

used to detect RT activity in plasma samples.
Preliminary experiments were performed using a positive control
consisting of human plasma to which known amounts of RLV were added.
Attempts to detect RT in positive plasma control samples were
negative unless the manganese cation was added to the reaction
mixture.

Table 6 presents the results of RT assays performed to

determine the optimal concentration of NP-40.
tration range found was 0.10-0.25%. These results
previous report
has been shown

The optimum concen
confirm a

(19) that the reaction was dependent on NP-40.

It

(19) that there is a direct relationship between

protein concentration and NP-40 concentrations for this assay,
i.e., less NP-40 is required at low protein concentration and vice
versa.
(19,31)

It was determined in this laboratory and other laboratories
that much lower concentrations of NP-40 were optimum for

reactions not involving protein.

This optimum concentration was

0.03%.
A report by Mueller
RT activity.

(38) had suggested that heparin inhibited

The inhibitory effect on RT activity of various

anticoagulants are presented in Table 7.

As compared to virus RT

activity in virus buffer, all reagents showed some inhibition.
Clearly heparin showed complete inhibition while EDTA and glass
beads ranked b e low CPD.

Since glass beads were essentially inert

the observed inhibition m ight have been due to plasma inhibitors
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and/or to heparin which might have been released from disrupted
white blood cells.

To determine whether the inhibition noted may

be a combination of the factors in the plasma and the method of
collection, an experiment with virus added to virus buffer or to
virus buffer with EDTA

(1.44 mg/ml) was carried out.

As shown in

Table 8 EDTA caused about 13% inhibition while heparin was
completely inhibitory.

From Table 7 it can be seen that when the

RT activity in the plasma collected with EDTA was compared to virus
in virus buffer there was about 4 2% inhibition.
The potency of heparin as an inhibitor could be a factor in
the assay of RT activity from certain tissues which might contain
naturally occuring heparin.

Table 9 presents data illustrating

that, even with a 1000-fold dilution of plasma particulate fraction
collected from heparinized plasma,

there was significant inhibition

of RT activity when compared to EDTA plasma.

This demonstrated that

at least 66% of the available RT activity was masked by heparin
inhibition.

A 10-fold dilution of plasma particulate fraction

prepared from EDTA treated plasma abolished RT inhibition entirely.
Although the plasma was collected with a known amount of heparin, the
concentration of heparin in the plasma particulate fraction was
unknown b u t was assumed extremely low.
It was of interest, since heparin might be used as a metabolic
inhibitor,

to determine whether the reverse transcription step or

the normal DNA to DNA transcription step or both was inhibited by
heparin.

As shown in Figure 4, heparin added to the RT reaction at

5 minutes or 15 minutes caused immediate inhibition of the incorpor
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ation of H-^-TTP.

Since the RNA template specific activity of RT was

completed during the initial 10 minutes

(35), the results in Figure

4 demonstrated that heparin inhibited both the RNA-dependent and
DNA-dependent enzyme activities.
It should be noted that although
^ ^ '
the reaction was stopped at these times, the amount of product
remained constant demonstrating that the DNA product was stable
over the incubation period.
The results of these experiments showed EDTA was the anti
coagulant of choice because it caused least inhibition of the
assay.

Plasmas were collected in EDTA-Vacutainers from 22 patients

with various malignancies such as leukemias,
cancers.

One case each of a colon cancer and a melanoma were

included in the assay.

O f the plasmas assayed none showed TMP

incorporation over backround.
31,32,33)

lymphomas and breast

Since other workers

(26,27,28,29,30,

had demonstrated RT activity with the same type of

malignancies it was obvious that a reevaluation of the assay method
was necessary?.
When a known amount of RT, in the form of virus, was added to
p lasma the recovery of the RT activity was only 10-15% of the
activity obtained when the RT was assayed without plasma presence
or centrifugation.

The lowered recovery of virus particles was

apparently due to the formation of a pellet which could not be
completely resuspended.
Buthala

Next a procedure used by Mathews and

(39) to form an even layer of virus particles instead of a

clumped pellet was attempted.

This newer method used a flat-topped

teflon boss in the b o t t o m of the centrifuge tube, supporting a flat
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collecting surface for collecting virus particles.

Plasma,

contaminated with RLV particles, when sedimented at 31,000 x g for
10 minutes at 4°C consistently had a recovery rate of 50% when
calculated as the previous recovery rate.
Theoretically a 100 my particle,

the approximate size of

oncornaviruses, will take 130 minutes at 31,000 x g to be pelleted
Although little RT activity would be expected using method III, th
pellet from contaminated plasma incorporated 2.41 picomoles of TMP
Even at 38,000 x g, a 100 m

particle would be expected to require

20 minutes to sediment 99.9% of the particles.

To establish that

this unusual result was not dependent only on the presence of
plasma,

the same amount of virus,

3 x 10

virus buffer and treated identically.

Q

virions, was added to

An incorporation of 3.64

picomoles of TMP was found with pelleted material.

When the

supernatant was further centrifuged at 215,000 x g for 30 minutes
at 4°C,

sufficient to pellet 99.9% of the remaining virus

particles, only 0.15 picomoles of TMP incorporation due to RT
activity was detected.

These results indicated that the RLV

particles formed aggregates when in human plasma or virus buffer,
and that 96% of the virus particles

(in virus buffer)

could be

pelleted by centrifugation at 31,000 x g for 10 minutes at 4°C.
Only 64% of the available particles in plasma were pelleted.

The

question remains as to whether the plasma particulate fraction
interfers with the RT assay or whether the plasma itself impedes
sedimentation.

Using this procedure it was calculated

that approximately 1 0 7 virions per ml of human plasma

(Table 10)
(collected
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with CPD) was the minimum concentration detectable.
To attempt further dispersion of the virus particles the
mucilaginous material deposited on the coverslip was treated with
hyaluronidase with the results x^resented in Table 10.

Although the

mucilaginous material dissolved, as noticed by visual observation
after 10 minutes preincubation at room temperature, the use of the
hyaluronidase during the preincubation did not affect the percent
recovery

(see Table 10).

The incubation of the coverslip and virus

with hyaluronidase over a 24 hour period,
hyaluronidase treatment,
In view of these results,

to ensure complete

resulted in a decreased TMP incorporation.
it was decided that use of hyaluronidase

was of no benefit as a solubilizing agent.
Using clinical x^eparation method II, four different subjects
were examined for presence of RT activity in x^lasma collected with
EDTA.

One patient had clinically evident acute granulocytic

leukemia

(AGL)

individuals.

and the other three subjects were normal healthy
These results are presented in Table 11.

Plasma

samples were taken from the cancer patient on three different dates.
The levels of TMP incorporation in all subjects was low, and no
significant difference was seen between the normal subjects and
the cancer patient.

It should be remembered that this method had

an enzyme recovery rate of only 10-15%.
Later, the improved preparation method III was used

(Table 12)

to analyze the RT activity in plasmas of 12 additional patients.
One normal subject, IC and the AGL patient, W, were included within
the sample.

Even though the percent recovery of enzyme activity
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was 50% using this method, low levels of TMP incorporation were
again found in all subjects.

No significant difference between

normal and cancer subjects, using the magnesium cation, was
observed.

Since,

as stated earlier, the manganese cation increases

the sensitivity of the enzyme assay, replacement of the magnesium
cation with manganese was attempted in a normal and an AG L subject.
As reported in Table 12, a greater sensitivity was observed using
this cation.

Although more TMP incorporation was found, less RT

activity was observed in the AGL patient than in the normal subject.
Because of the apparent lack of specificity,

as predicted

(37), use

of the manganese cation was discontinued.
The RT assay was developed to yield presumptive evidence
predicting malignancy.

Although no oncornavirus has yet been

demonstrated as an etiologic agent for a human malignancy, evidence
(26,27,28,29,30,31,32)

indicates that some malignant diseases

increase the RT activity in human tissues.

No significant

difference was observed between the enzyme activities of normal and
cancer subjects.
and lymphomas
Therefore,

Evidence of others predicted that some leukemias

(26,27,29,30) would have elevated enzyme activities.

it must be concluded that the enzyme assay was not

successfully adapted as a rapid screening procedure for any
malignancy tested.
An attempt was made to determine whether RT activity could be
correlated with virus titer in tissue culture fluid.

This would

provide an investigator with a simple and rapid assay procedure.
RLV sample obtained from the laboratories of The Upjohn Company
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A

having a titer with 2.6 x 10

infectious units per ml of tissue

culture fluid was assayed for RT activity two different times.

The

virus h a d been stored frozen and the titer was established only
before storage at -90°C.

The preliminary assay showed a titer of

0.23 picomoles per ml and after one month, using another sample,
a titer of 0.07 picomoles per ml was found.

The first sample volume

was only 0.3 ml compared to a much larger 1.75 ml in the second RLV
sample.

Because the results with the enzyme assay showed a three

fold difference and because this assay system has been shown

(page

16) to detect only one-half a power of ten difference in virus
concentration,

use of the RT assay system to quantitate viral

presence is limited.
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SUMMARY

This study was originally designed to examine rapid, clinically
suitable methods to detect cancer using the criteria of RT activity.
RT had be e n demonstrated by others

(26,27,28,29,30,31,32,33)

a potential predictive signal of some forms of oncogenesis.

to be
Three

assay methods were tested, with the selection of the procedure
described by Roy-Burman
1) virus presence,
4) detergent

(34).

The procedure was dependent on:

2) RNA template presence,

(NP-40)

concentration.

3) specific cations,

and

Although the enzyme assay was

d ependent on the specific cation used, others

(37) had reported

that the manganese cation was less specific for the RNA template
than was the magnesium cation.

Perhaps the manganese cation acts

to shift the equilibrium of the reaction toward DNA replication
and the early enzyme activity dependent on a RNA template is
shortened.
Heparin and other anticoagulants were shown to cause inhibition
of the RT activity in biological samples

(Tables 7 and 8).

Inhibition by heparin was especially significant because of its
possible presence in biological samples.
affected both early
template)

(RNA template)

The heparin inhibition

and late transcription

(DNA

suggesting that it was not a selective inhibitor of RT.

As the methods for adapting Roy-Burman's assay method to a
clinical system evolved,

attempts were made to increase the recovery

of virus from the collected plasma samples.

Originally the

24
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procedure was capable of recovering 10-15% of the available RT
activity, but after modifying the procedure to avoid a pellet,
recovery of 50% was achieved.
clinical assay method,
while in solution.

Also, during the evolution of the

it was shown that the virions aggregated

The final procedure for use in clinical systems

was able to detect approximately 10

7

virions per ml of human plasma

or greater.
Plasma particulates from normals and patients with malignancies
were assayed for RT.

No significant difference was found between

normal subjects and subjects with malignancies.

The lack or

significant difference was probably due to the inability of the
assay to detect the levels of RT found in human plasma.

Still,

the

possibility of RT not being present at any level within the samples
tested cannot be discounted.

Because of these results it was

concluded that the clinical assay system developed was not suitable
for detecting differences in RT activity between subjects.
Although the clinical assay system was not able to detect RT
activity in the subjects tested, an attempt to demonstrate the
utility of this procedure to detect oncornaviruses in tissue
culture was made.

Because this system was biologically less

complex, some utility was shown in preliminary experiments.

More

work will need to be done to further establish the effectiveness
of the assay in tissue culture.
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FIGURE 1. - Molecular-Genetics Model
Known in 1964
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FIGURE 2. - Thymidine Incorporation due to RT
using Method l^a ^
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FIGURE 3. - Thyinidine Incorporation due to RT
using Method II^a ^
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60

FIGURE 4. - Heparin as a Metabolic I n h i b i t o r ^
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TABLE 1. - Reagents for the Reaction Mixture
or Assay Method I
(a)
Reagent

Amount

Tris (hydroxmethyl) aminomethane
hydrochloride (Tris)

8.0 ymoles

UaCl

12.0 pmoles

MgCl

•6Ii20

1.2 ymoles

Reduced glutathione

0.74 ymoles

Dllase nicked myeloblastic DNA

0.01 ml

H^-thymidine 5*-triphosphate
Thymidine 5'-triphosphate

(II^OTTP)

4.0 pmoles

(TTP)

Deoxycytidine 5'-trii^hosphate

0.02 yCi

(dCTP)

0.4 nmoles

Deoxyadenosine 5'-triphos£3hate

(dATP)

0.4 nmoles

Deoxyguanosine 5'-triphosphate

(dGTP)

0.4 nmoles

a

Abbreviations are:
micromoles = ymoles, curies per millimolar =
Ci/mM, picomoles = pmoles, and nanamoles = nmoles, microcuries =

yci
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TABLE 2. - Reagents for the Reaction Mixture
of Assay Method II

Reagents
Tris

Amounts

(pH 3.3)

5.0 ]jMoles

M g C l 2 *6II20

0.37 ymoles

HaCl

0.21 ymoles

dATP

0.16 ymoles

dCTP

0.16 ymoles

dGTP

0.16 ymoles

TTP

0 .37 nmoles

H 3-TTP

0.02 yCi
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TABLE 3. - Reagents for the Reaction Mixture
of Assay Method III
(a)
________________Reagents________________________________________ Amounts
Tris

(pH 7.9

5.0 ymoles

MgCl2*6H20

0.5 ymoles

NaCl

2.0 ymoles

DTT

0.5 ymoles

NP-40

0.02 yl

Oligo dT'poly rA

2.0 yg

H 3-TTP

2.0 yCi

aAbbreviations are the same as in Table 1 with the addition of:
micrograms = yg
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TABLE 4. - Picomoles of TMP Incorporated
at Various RLV Dilutions

TMP I n c o r p o r a t i o n ^ ' 0 ^ (picomoles)
Actual______________ Expected

f—1
o
CO

Virions per milliliter

1.39

---

6.6 X 10 7

0.06

0.13

6.0 X io6

0.01

0.01

5.5 X 105

0.00

0.00

o
•
in

0.00

0.00

7.2 X

X 104

The samples were preincubated in 0.03% HP-40 for 4 5 minutes at
4°C and then incubated for 30 minutes at 37°C with method III
(all samples were in virus buffer)

Calculated from the dilution factor and the TMP incorporation of
the undiluted sample (backround subtracted from all values)

Thymidine monophosphate = TMP
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TABLE 5. - Sensitivity of the Artificial
Template to RNase ^

Incubation Time
Rllase
TMP Incorporation
(minutes)_______________________________________________ (picomoles)
0

absent

0.00

0

present

0.00

30

absent

0.22

30

present

0.01

i samples were preincubated in 0.03% NP-40 with RNase
13 milligrams per ml) or without for 45 minutes at 4°C

38
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TABLE Jo. - Effect on HP-40 Concentration
on RT Assay

Final Concentration of HP-40
TMP Incorporation
_________ (percent)_________________________________________(picomoles)

a

0.05

0.04

0.10

0.05

0.25

0.05

0.50

0.02

O
After adding 10 virus particles to human plasma collected with
the anticoagulant, heparin, the virus particles were separated
from the p lasma by centrifugation at 215,000 x g for 30 minutes
at 4°C.
This pellet was resuspended in various concentrations
of HP-40 in 0.1M DTT and examined for RT activity with enzyme
method III.
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TABLE 7. - The Effect of Various Anticoagulants
on RT Activity in Plasma

Anticoagulant

ul of RLV

TMP

I n c o r p o r a t i o n to)

(picomoles)______
EDTA

(1.44 mg/ml)

Glass beads

100

0.72 4* 0.03

100

0 .66 + 0.03

50

0.00

CPD to)

100

0.83

CPD(b )

50

Heparin

(28.6 USP/ml)

Virus buffer

(no plasma)

100

+

0.03

0.41 + 0.02
1.24

+

0.05

a
All reactions were incubated for 30 minutes at 37°C
b
These values were not obtained at the same time as other values
presented.
The value for CPD with 50 y 1 of RLV was the average
of two different days, each run in triplicate.
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TABLE 8. - The Effect of EDTA and Heparin on RT
Activity in Virus B u f f e r ^

Anticoagulant

None
EDTA

(1.44 mg/ml)

Heparin

(2.40 USP/ml

TMP Incorporation
(picomoles)

% Inhibition

0.78 + 0.03

n

0.G8 + 0.03

13

0.00

100

a
All reactions were incubated for 30 minutes at 37°C with
1.5 x 10° virus particles per reaction mixture
b
Percent inhibition calculated by comparison to no anticoagulant
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TABLE 9. - Effect of Diluting the Anticoagulant
on the RT Activity

Dilution
Anticoagulant^)
XMP Incorporation
________________________________________________________ (picomoles)
No Dilution

EDTA

0.46

1:10

EDTA

0.98

1:1000

EDTA

0.88

No Dilution

heparin

0.00

1:10

Heparin

0.01

1:1000

Heparin

0.66

a
All reactions were carried
out at 37°C for 30 minutes with a virus
Q
concentration of 3 x 10 particles per reaction
b
The concentration of EDTA was 2.44 rng/ml and the concentration
of heparin was 28.G USP/ml

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

TABLE 10. - Use of Coverslip and Hyaluronidase to
Increase the Percent Recovery of RT
Using the Clinical Sample Preparation
Methods II and III

Clinical
Methods

Hyaluronidase^

TMP Incorporation
(picomoles)

%

R e c o v e r y

II

none present

0.14

32

III

none present

0.44

100

III

present during
preincubation

III

present 24 hours
prior to
preincubation

0.43

98

0.27

61

a
The hyaluronidase (Wydase) concentration was 37.5 HF units per
preincubation volume.
The visible mucoid substance was absent
after incubation with hyaluronidase.
b
% Recovery was calculated by comparison to method III with no
hyaluronidase present
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(k)

TABLE 11. - RT Levels in Human Plasma
Using the Method II

Date
Patient
Diagnosis^
TMP Incorporation
____________________________________________________________(picomoles)_____

5-4

W

AGL

0.01

5-7

W

AGL

0.00

5-10

K

Normal

0.01

5-10

H

Normal

0.02

5-10

Wa

Normal

0.02

5-14

w

AGL

0.01

ci
Abbreviations:

AGL = acute granulocytic leukemia
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TABLE 12. - Levels of RT in Various Cancer Patients
Using the Clinical Sample Preparation
Method III

Date

Patient

Diagnosis

TMP Incorporation
(picomoles)
___________________________________________________________Mg___________ Mn
5-24

B

AGL

0.02

-

5-24

P

CGL

0.02

-

6-6

Pe

ALL

0.01

-

6-6

W

AGL

0.01
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Abbreviations:
AGL = acute granulocytic leukemia, CGL = chronic
granulocytic leukemia, and ALL = acute lymphoblastic leukemia
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